The Strategic Role and Evolving Landscape of the Life Sciences Research Activities Credit in Iowa

The Life Sciences qualifying industry broadly encompasses the sciences concerned with the study of living organisms, including subjects like agriscience, biology, botany, zoology, microbiology, physiology, and biochemistry.1 This designation allows businesses engaged in technical research activities within these fields to claim the valuable, refundable Iowa Research Activities Credit (RAC), a critical tool for funding innovation and economic growth.

The Iowa Research Activities Credit (RAC) is a cornerstone of the state’s incentive portfolio, specifically designed to spur innovation by providing tax relief on qualified research expenditures (QREs). For Life Sciences firms, the RAC has historically provided a substantial, largely uncapped, and often refundable tax benefit on incremental research expenses.3 However, recent legislative changes culminating in a significant structural overhaul scheduled for January 1, 2026, introduce new administrative hurdles, annual caps, and lower rates, demanding immediate strategic planning to maximize current benefits and prepare for a more competitive and constrained future landscape.3

Defining the Life Sciences Qualifying Industry in Iowa

The definition of “Life Sciences” is a critical starting point for any Iowa firm seeking this tax benefit, as engagement in a qualifying industry is a non-negotiable prerequisite for claiming the state RAC.1

Statutory Foundation: The Detailed Context

The precise definition is rooted in the Iowa Administrative Code, specifically rule 701—304.11, which explains terms necessary for claiming the credit.2 Under this guidance, Life Sciences is defined as the sciences concerned with the study of living organisms, including but not limited to: agriscience, biology, botany, zoology, microbiology, physiology, biochemistry, and related subjects.1

The phrase “and related subjects” offers necessary flexibility, allowing the definition to cover modern interdisciplinary fields such as bioengineering, computational biology, and personalized medicine research, provided the activities fundamentally rely on the enumerated biological principles.2

The explicit inclusion of agriscience is particularly important within the context of Iowa’s economic profile.1 Iowa is recognized as a global leader in bio-industrial processing, including significant production of ethanol and biodiesel, and is home to a high concentration of plant and soil scientists.7 The state tax policy reflects this strategic focus by extending the Research Activities Credit not only to human pharmaceutical research (like biochemistry or microbiology) but also to companies developing innovations in crop genetics, advanced soil science, and agri-industrial processing. This structural inclusion solidifies the RAC as a core incentive supporting the state’s agricultural technology sector.7

Contextualizing Life Sciences Activities

To qualify for the credit, a firm must demonstrate that its research activities align with the principles inherent in the Life Sciences definition. Examples of qualifying research projects frequently seen in this sector include:

• Pharmaceutical and Therapeutic Development: This involves the synthesis and optimization of new chemical compounds intended for drug candidates, often requiring experimentation to determine the optimal synthesis pathway to ensure purity and yield at scale.8
• Medical Device Innovation: Research related to new generations of complex medical devices, such as those for fluid management during surgery, often involves significant software and hardware modifications. Qualification stems from overcoming substantial technical uncertainty related to pressure accuracy, flow rate maintenance, or specialized algorithms.8
• Bio-Industrial Processing and Bioproducts: Activities centered on optimizing fermentation yields, developing new bioproducts, or improving the efficiency and sustainability of ethanol or biodiesel production.7
• Animal Health Research: Research focused on animal vaccine development and therapeutic advancement, a sector in which Ames, Iowa, is a national hub for innovation.7

Core Research Activities Credit (RAC) Eligibility

Eligibility for the Iowa RAC is governed by a strict dual compliance standard established by the 2018 Iowa Tax Reform Bill (Senate File 2417).1

The Dual Eligibility Requirement

For tax years beginning on or after January 1, 2017, a business must meet two mandatory requirements to claim the Iowa credit 1:

1. Federal Claim Requirement: The taxpayer must successfully claim and be allowed a Federal Research Credit for qualified research expenses (QREs) under Internal Revenue Code (IRC) section 41 for the same taxable year.1
2. Industry Requirement: The business must be engaged in one of the specific qualifying industries defined by Iowa law: Manufacturing, Life Sciences, Software Engineering, or Aviation & Aerospace.1

The requirement that the state claim is contingent upon the federal allowance means that state tax compliance is inherently dependent on robust documentation and compliance with federal rules. If a taxpayer fails to sustain their federal claim under audit, the corresponding Iowa claim will be invalidated, potentially leading to state interest and penalties.1

Qualified Research Expenditures (QREs) and the Four-Part Test

Even if a Life Sciences firm meets the industry requirement, the specific expenditures must qualify as QREs under the long-standing federal four-part test, which Iowa uses to define its own qualified activities.9 The activities must satisfy all four criteria:

1. Technological in Nature: The activities must fundamentally rely on the principles of physical or biological science, engineering, or computer science.9
2. Permitted Purpose: The research must be aimed at improving the functionality, performance, reliability, or quality of a new or existing business component (product, process, or software).9
3. Eliminate Uncertainty: The primary goal must be to resolve technical uncertainty regarding the capability, method, or design of the product or process.8
4. Experimentation: The process must involve a systematic trial-and-error approach, testing, or modeling designed to evaluate alternatives and eliminate the identified uncertainty.8

For Life Sciences companies, QREs typically include the wages of researchers and engineers directly involved in systematic experimentation (e.g., laboratory testing, algorithm development) and certain contract research expenses. Expenses related to routine testing or quality control conducted after technical uncertainties have been resolved are generally excluded.8

Iowa Department of Revenue (IDR) Guidance and Calculation Mechanics (Current Law)

Prior to the structural changes slated for 2026, the Iowa RAC is administered by the Iowa Department of Revenue (IDR). Taxpayers report the credit using Form IA 128 (Regular Method) or IA 128S (Alternative Simplified Credit), selecting the same method used for their federal research credit calculation.11 The final claim is reported on the IA 148 Tax Credits Schedule using tax credit code 58.11

The Regular Research Activities Credit (IA 128)

The Regular Credit is calculated as 6.5% of the Iowa-apportioned excess of current QREs over the statutory base amount.10

The clarification provided by the 2018 Iowa Tax Reform Bill details how the base amount is determined: it is the product of the fixed-base percentage multiplied by the average annual gross receipts for the four preceding taxable years.1

A critical nuance in the current law is the 50% QRE Floor. The statute dictates that the calculated base amount in no event shall be less than fifty (50) percent of the qualified research expenses for the credit year.1 This floor significantly constrains the credit generation for businesses experiencing rapid growth or volatility in R&D spending. If a Life Sciences startup has negligible prior gross receipts, the calculated traditional base may be near zero. In this instance, the 50% floor immediately takes effect, forcing half of the current QREs to be excluded from the incremental calculation. This effectively caps the maximum claimable credit at 3.25% (6.5% multiplied by the remaining 50% of QREs) of the total current QREs, impacting strategic financial modeling for these high-growth firms.10

The Alternative Simplified Credit (ASC) Method (IA 128S)

If a taxpayer elects or is required to use the federal Alternative Simplified Credit (ASC), they must use the IA 128S form for Iowa.11

The ASC calculation rate is $4.55\%$ of the incremental research expenditures.10 Under this method, the base is defined as $50\%$ of the average Iowa QREs from the three preceding taxable years. If a taxpayer had no QREs in those prior years, the base is $0\%$.10

Table 1: Key Differences: Iowa RAC Calculation Methods (Pre-2026)

The Supplemental Research Activities Tax Credit (SRAC)

Iowa offers an enhanced benefit known as the Supplemental Research Activities Tax Credit (SRAC). This credit is not available automatically; it is only awarded to taxpayers who have been approved by the Iowa Economic Development Authority (IEDA) under the High Quality Jobs Program (HQJ).11

The HQJ program is fundamentally an economic development initiative designed to promote business growth and encourage the creation or retention of high-quality, high-wage jobs within Iowa.13 Accessing the SRAC requires a Life Sciences company to negotiate and execute an HQJ agreement, often involving commitments to specific capital investment and job creation targets.13

The SRAC rates are tiered based on the eligible business’s gross revenues 10:

• Small/Mid-Sized Businesses: For businesses with average gross revenues of $20 million or less, the supplemental credit cannot exceed $10\%$ of the qualified research expenditures eligible for the regular RAC calculation.10
• Large Businesses: For businesses with gross revenues exceeding $20 million, the supplemental credit cannot exceed $3\%$ of the qualified incremental research expenditures.11

For a smaller Life Sciences firm utilizing the Regular Credit method, the potential combined incremental rate is exceptionally generous: $6.5\%$ (RAC) plus up to $10\%$ (SRAC). This total potential $16.5\%$ applied to incremental QREs makes the overall Iowa R&D incentive highly attractive for firms that align their R&D strategy with the state’s economic development goals under the HQJ program.10

Case Study: RAC Application for an Iowa Life Sciences Firm

This case study demonstrates the process of qualification and the calculation mechanics, highlighting the effect of the incremental structure and the supplemental credit.

Scenario Setup: Bio-Pharmaceutical Process Optimization

Iowa Life Sciences LLC (ILS) is a mid-sized bio-pharmaceutical company in Coralville, specializing in novel compound synthesis, an activity that qualifies under the Life Sciences definition (Biochemistry/Physiology).1 ILS successfully secured a High Quality Jobs (HQJ) award, making it eligible for the SRAC.11

The project involves optimizing a complex chemical synthesis pathway, resolving technical uncertainty related to achieving consistent yield and purity at manufacturing scale, thus meeting the four-part test for QREs.8

Financial Data (Tax Year 2024):

• Total Iowa QREs for 2024: $1,000,000.
• Average Iowa Gross Receipts (Prior 4 Years): $12,000,000.
• Fixed-Base Percentage: 10%.
• Average Gross Revenues (Relevant for SRAC): $18,000,000 (qualifies for 10% SRAC).11

Step-by-Step Calculation Example (Regular Method)

Step 1: Calculate the Statutory Base Amount (IA 128)

1. Traditional Base Calculation: Fixed-Base Percentage (10%) $\times$ Avg. Gross Receipts ($12,000,000) = $1,200,000.
2. 50% QRE Floor Check: 50% $\times$ Current QREs ($1,000,000) = $500,000.
3. Base Amount Used: The statute requires the base to be the greater of the traditional calculation or the 50% floor.1 Since $1,200,000 is greater than $500,000, the base used is $1,200,000.

Step 2: Calculate Incremental QREs and Regular RAC

1. Incremental QREs: Current QREs ($1,000,000) – Base ($1,200,000) = $-\$200,000$.
2. Regular RAC: $6.5\% \times (-\$200,000) = **\$0**$.

This result demonstrates that the Iowa RAC is strictly an incremental credit. Life Sciences firms with substantial, long-term business histories and consistently high gross receipts relative to current R&D investment may find that their high historical base amount excludes them from receiving the Regular RAC, even with significant current QREs.1

Alternative Scenario: High-Growth Startup (Where 50% Floor Applies)

To illustrate the benefit for rapidly growing Life Sciences firms, assume the same $1,000,000 QREs, but the 4-year average gross receipts were only $3,000,000 (Traditional Base: 10% $\times$ $3,000,000 = $300,000).

1. Base Amount Used: The base is capped at the greater of the Traditional Base ($300,000) or the 50% Floor ($500,000).1 Base amount used is $500,000.
2. Incremental QREs: $1,000,000 – $500,000 = $500,000.
3. Regular RAC: 6.5% $\times$ $500,000 = $32,500.

Step 3: Calculate Supplemental RAC (Based on High-Growth Scenario)

1. Supplemental Rate: 10% (Gross Revenue $\le\$20M$).11
2. Supplemental Credit: 10% $\times$ Incremental QREs ($500,000) = $50,000.
3. Total Combined Credit: Regular RAC ($32,500) + Supplemental RAC ($50,000) = $82,500.

Compliance, Administration, and Reporting

Compliance requires diligent record-keeping of QREs and strict adherence to Iowa’s filing procedures. Taxpayers use either the IA 128 or IA 128S forms to compute the credit and must then transfer the final amount to the IA 148 Iowa Tax Credits Schedule, using tax credit code 58.11

In cases where the research credit is earned by a pass-through entity (such as a partnership, Limited Liability Company, S-corporation, estate, or trust), the credit must be claimed by the individual owners based on their pro rata share of the entity’s income, necessitating careful flow-through documentation.11

Both the RAC and the SRAC are generally considered refundable credits.5 Historically, the refundability percentage has been high (for example, 80% for RAC and 90% for SRAC), allowing Life Sciences companies that may not yet have tax liability to receive a cash refund to fund prototypes or further R&D.10

Strategic Outlook: Navigating the 2026 Legislative Transformation

Effective for tax years beginning on or after January 1, 2026, the Iowa R&D tax credit regime will undergo a fundamental structural transformation, presenting significant strategic challenges for Life Sciences firms.3

Administrative Shift and Compliance Burden

Beginning in 2026, the administration and oversight of the research credit shifts entirely from the Iowa Department of Revenue (IDR), which handles traditional tax filing, to the Iowa Economic Development Authority (IEDA).3

This shift mandates new compliance requirements: the new R&D Tax Credit requires mandatory IEDA pre-approval before research begins, along with independent CPA validation of claims.3 This converts the incentive from a post-expenditure, self-assessed tax deduction (under the IDR) to a competitive, pre-certified economic development grant model (under the IEDA). Life Sciences firms must integrate the IEDA application and approval timeline—potentially requiring certification months before expenditures occur—into their annual R&D budgeting process, and must also account for increased annual compliance costs due to the required CPA validation.3

Financial and Programmatic Restrictions

The new R&D Tax Credit, which replaces the uncapped RAC, introduces strict financial limits 3:

1. Reduced Credit Rate: The maximum credit rate drops substantially from the current 6.5% (Regular RAC) to 3.5% of qualifying in-state QREs.3
2. Statewide Annual Cap: The incentive will be constrained by a hard $40 million annual statewide cap.3

The imposition of a capped, pro-rata allocation system introduces considerable financial uncertainty. If the total certified R&D expenses from all qualifying firms exceed the $40 million annual cap, the IEDA is required to allocate the credits proportionally.3 Life Sciences firms that historically relied on the full $6.5\%$ rate being refundable to secure R&D funding may find their anticipated cash flows significantly reduced. Strategic financial modeling must incorporate a risk factor below the $3.5\%$ statutory maximum to account for potential pro-rata reduction.

Future Industry Scope: Life Sciences to Bioscience

The new R&D credit program is limited to four specific industries: Advanced Manufacturing, Bioscience, Insurance/Finance, and Tech/Innovation.3

The existing broad “Life Sciences” category, which explicitly included specific research areas like agriscience, botany, and zoology 2, is replaced by the potentially narrower term “Bioscience”.3 While bioscience generally covers the study of life and its applications, the IEDA must issue new regulatory guidance following the 2026 implementation to explicitly confirm whether the expansive scope established under the current definition (IAC 701—304.11) will be fully maintained under the new “Bioscience” definition.3

Table 2: Comparison of Iowa R&D Incentive Programs (Current vs. Post-2026)

Conclusion and Actionable Recommendations

The Iowa Research Activities Credit (RAC) currently serves as an aggressive incentive for Life Sciences investment, particularly when combined with the Supplemental RAC (SRAC) awarded through the High Quality Jobs Program, which can increase the effective incremental credit rate to as high as $16.5\%$ for smaller firms. The state’s definition of Life Sciences is intentionally broad, encompassing critical agricultural and animal health research sectors vital to Iowa’s economy.7

However, the impending transition in 2026 necessitates an immediate shift in strategic planning. The future program is defined by lower rates, a hard monetary cap, and increased administrative complexity through the IEDA pre-approval and validation requirements.3

Actionable Recommendations for Life Sciences Firms

1. Maximize Pre-2026 Claims: Businesses must accelerate eligible R&D expenditures into the 2024 and 2025 tax years to secure benefits at the higher $6.5\%$ rate and benefit from the program’s current uncapped refundability.3
2. Ensure Robust Federal Compliance: The Iowa credit is wholly dependent on a successful federal IRC $\S41$ claim. Life Sciences firms must maintain exhaustive documentation to support the federal four-part test, ensuring the QREs can withstand scrutiny at both the federal and state levels.1
3. Model the 50% QRE Floor Correctly: Life Sciences startups and high-growth companies must accurately model their credit using the IA 128 (Regular Method), paying particular attention to the mandatory $50\%$ QRE floor, which significantly impacts the calculation of incremental QREs for firms with low historical gross receipts.1
4. Prepare for IEDA Administration: Businesses should begin coordinating with tax advisors and economic development consultants now to understand the new IEDA pre-approval and annual certification processes required to access the 2026 R&D Tax Credit, incorporating the enhanced compliance costs and timelines into future budgets.3
5. Monitor Industry Scope Guidance: Firms engaged in ancillary Life Sciences fields, such as agriscience or zoology, must closely monitor IEDA guidance following the 2026 transition to confirm that the specific components of the current “Life Sciences” definition are officially retained under the new “Bioscience” category.2

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/